Health Care

Replimune Group Inc. pioneers oncolytic immunotherapy, aiming to selectively kill cancer cells while sparing healthy tissue. Learn about its clinical trials, market performance, and future oncology impact.

Explore how Eckert & Ziegler’s latest lead‑212 supply deal and theranostics forum boost alpha‑emitter therapies, positioning the German firm at the forefront of nuclear medicine innovation.

Shenzhen Salubris Pharmaceuticals: 374.5 billion‑CNY cap, 55.95 P/E, and robust R&D drive shows its strategic edge in tablets, capsules, and injectables – poised for future growth.

Satellos Bioscience, Toronto‑based biotech, advances SAT‑3247 for muscular dystrophy, with Phase II trials and investor talks at key conferences.

Explore XCELERATE INC’s health‑care stock performance, valuation, and its partnership with Union Dental Holdings—gain insights into volatility and future prospects.

BriaCell’s Phase III Bria‑ABC study gets sixth consecutive DSMB endorsement, confirming safety and paving the way for fast‑track approval in metastatic breast cancer.

Echo Lake Capital offers $4.00/share for Aclarion Inc. (NASDAQ: ACON) amid board governance concerns. Aclarion defends its MRS tech, AI platform, and upside potential from a reverse takeover. Discover the proposal’s details and the company’s growth …

Pfizer’s silent insiders, strong dividend yield, and FDA vaccine outlook paint a clear picture: a steady, income‑focused stock amid regulatory shifts and analyst optimism.

Q‑C Technologies Inc. faces steep stock volatility, a negative P/E, and financial uncertainty despite promising drug‑development goals in aging, pain and sleep disorders.

Strides Pharma Science’s latest SEBI filing confirms no new share encumbrances, underscoring its commitment to transparency, market confidence, and regulatory compliance.